When genetic test results for your patients come back with variants of unknown significance, how do you truly determine hereditary cancer risk and provide medical management recommendations? What if there’s a solution for DNA testing’s limited interpretations?
In this webinar, we share our experience pairing DNA and RNA sequencing to yield more accurate results. We’ll include an in-depth look at several cases to illustrate the potential benefit to individuals and their families.
Questions We’ll Answer:
- How is RNA evidence interpreted and applied toward variant classification?
- How does improved test accuracy translate to clinical significance for high-risk cancer patients? (Presented with case examples!)
Presenters
Carrie Horton, MS, CGC
Sr. Clinical Researcher Specialist
Terra Brannan, PhD
Variant Assessment Scientist
Jessica Grzybowski, MS, CGC
Lead Genetic Counselor
![overlay-bottom[1]](https://ambrygen.com/wp-content/uploads/2026/02/overlay-bottom1.svg)